|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
|3.||Nail Diseases (Nail Disease)
|4.||Joint Diseases (Joint Disease)
|1.||McGonagle, Dennis: 2 articles (12/2015 - 05/2007)|
|2.||Ioannides, D: 2 articles (05/2010 - 08/2008)|
|3.||Rigopoulos, D: 2 articles (05/2010 - 08/2008)|
|4.||Gregoriou, S: 2 articles (05/2010 - 08/2008)|
|5.||Krueger, Gerald G: 2 articles (04/2009 - 05/2007)|
|6.||Scher, Richard K: 2 articles (02/2008 - 04/2006)|
|7.||Gül, Ahmet: 1 article (12/2015)|
|8.||Mahr, Alfred: 1 article (12/2015)|
|9.||Direskeneli, Haner: 1 article (12/2015)|
|10.||Aydin, Sibel Zehra: 1 article (12/2015)|
|1.||infliximab (Remicade)FDA Link
08/01/2008 - "Alphalthough there is no control group, this data suggests that infliximab is effective for psoriatic nail disease in the context of severe skin and joint involvement."
01/01/2013 - "Importantly, this case report supports the efficacy of infliximab in psoriatic nail disease in the context of severe skin and joint involvement. "
02/01/2008 - "Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P < .001). "
02/01/2008 - "Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year."
11/01/2012 - "Biologics, particularly infliximab and etanercept, have also demonstrated high efficacy in the treatment of severe nail disease. "
|2.||Antirheumatic Agents (DMARD)IBA
|3.||tazarotene (Tazorac)FDA Link
|4.||diazenedicarboxylic acid bis(N'-methylpiperazide)IBA
08/01/1999 - "Patients with psoriatic nail disease (180/221, 81%) had significantly greater number of involved distal interphalangeal (DIP) joints (p = 0.004). "
12/01/2009 - "Chinese patients with nail disease and DIP joints involvement have a significantly higher risk of developing deformed joints. "
09/01/1994 - "The topographic association of nail disease and involvement of the adjacent DIP joints suggests a common local inflammatory mechanism."
09/01/1994 - "Nail disease (67% of total) was more common in patients with DIP joint disease (27% of total) and was significantly associated with adjacent DIP joint disease. "
06/01/2000 - "There was a significant (P < 0.05) decrease in capillary loop density in patients with either psoriasis plus nail disease (14.5 +/- 5.7 capillaries per 3 mm field) or psoriasis plus nail and DIP joint disease (14.3 +/- 5. 0) when compared with controls (19.2 +/- 3.8). "
|5.||Adrenal Cortex Hormones (Corticosteroids)IBA
12/01/2004 - "Systemic corticosteroids and adjuvant immunosuppressants were effective in treating mucocutaneous lesions as well as nail disease. "
01/01/2015 - "For patients with significant nail disease for whom topical therapy has failed, treatment with adalimumab, etanercept, intralesional corticosteroids, ustekinumab, methotrexate sodium, and acitretin are recommended. "
07/01/2015 - "Clinical assessment (M0 and M6) included: BASDAI, HAQ, SPARCC, PASI and nail disease. "
04/01/2009 - "Efficacy assessments through week 24 included the American College of Rheumatology 20% improvement criteria (ACR20), the Psoriasis Area and Severity Index (PASI) in patients in whom at least 3% of the body surface area was affected by psoriasis at baseline, the Short Form 36 Health Survey (SF-36), the disability index of the Health Assessment Questionnaire (HAQ), the Nail Psoriasis Severity Index (NAPSI), the physician's global assessment of psoriatic nail disease, and enthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index). "
04/01/2009 - "Significant improvement was observed for other major secondary end points (the HAQ and the SF-36), the NAPSI, the physician's global assessment of psoriatric nail disease, and the PsA-modified MASES index in each golimumab group compared with placebo. "
|7.||Interleukin-17 (Interleukin 27)IBA
|8.||Interleukin-12 (IL 12)IBA
|9.||Ketoconazole (Nizoral)FDA LinkGeneric
|10.||Immunosuppressive Agents (Immunosuppressants)IBA
03/01/2009 - "Biological therapy usually is indicated for widespread psoriasis, but studies show that therapy directed at nail symptoms can be effective in the treatment of coincident nail disease."
01/01/2007 - "Biological therapy for psoriasis and psoriatic arthritis is now widely used, and early evidence indicates it may have significant benefit for some patients with psoriatic nail disease. "
|4.||Transplantation (Transplant Recipients)
02/10/2015 - "Development of therapeutics for management of nail diseases thus remains a challenge. "
02/10/2015 - "This article reviews the current knowledge and recent advances in the field of transungual drug delivery and provides guidance on development of topical/ungual therapeutics for management of nail diseases, with special emphasis on management of onychomycosis, the most common nail disease. "